文献速递外周动脉疾病

定向斑块旋切联合药物涂层球囊治疗股腘动脉病变的1年临床结局与危险因素分析

One-Year Clinical Outcome and Risk Factor Analysis of Directional Atherectomy Followed With Drug-Coated Balloon for Femoropopliteal Artery Disease.
PubMed 文献 · J Endovasc Ther · 2021-07-12

结果显示1年一期通畅率为80.8%,免于临床驱动靶病变血运重建(CD-TLR)率为92.2%,补救性支架置入率为2.4%。慢性完全闭塞(CTO)总长度(分层为≤5 cm、5-10 cm、>10 cm)是1年一期通畅率丧失和CD-TLR的独立危险因素。

要点

  • DA+DCB治疗FPAD的1年一期通畅率为80.8%,免于CD-TLR率为92.2%,补救支架率仅2.4%。
  • CTO长度>10 cm患者1年一期通畅率和免于CD-TLR率显著低于CTO≤10 cm者。
  • CTO总长度(≤5 cm、5-10 cm、>10 cm)是1年一期通畅率丧失和CD-TLR的独立危险因素。

核心结论

  • DA+DCB在真实世界临床实践中是治疗FPAD安全有效的血管内疗法,1年通畅率良好且补救支架率低。

研究设计与样本

  • 所有患者平均病变长度22.1 cm,慢性完全闭塞(CTO)平均长度8.3 cm,严重钙化占32.5%。

主要发现

  • 1年一期通畅率为80.8%,免于CD-TLR率为92.2%,补救性支架置入率为2.4%。
  • CTO>10 cm患者1年一期通畅率和免于CD-TLR率显著低于CTO≤10 cm患者。
  • CTO总长度(分层为≤5 cm、5-10 cm、>10 cm)被确定为1年一期通畅率丧失和CD-TLR的独立危险因素。

关键数值与推荐

  • 1年一期通畅率80.8%,免于CD-TLR率92.2%,补救性支架置入率2.4%。
  • CTO长度分层:≤5 cm、5-10 cm、>10 cm;CTO>10 cm者1年一期通畅率和免于CD-TLR率显著更低。

临床怎么用

  • 对于股腘动脉病变,DA+DCB可作为安全有效的血管内治疗选择,尤其适用于CTO长度≤10 cm者。
  • CTO长度>10 cm患者术后再狭窄和靶病变血运重建风险较高,需加强随访和监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study investigated the 1-year clinical outcomes of directional atherectomy combined with drug-coated balloon (DA + DCB) in femoropopliteal artery disease (FPAD) from real-world experience. MATERIALS AND METHODS: A retrospective study was conducted of patients treated between July 2016 and June 2019 using DA + DCB for FPAD. Patients' demographics, comorbidities, clinical characteristics and outcomes, and angiography and duplex ultrasound findings were analyzed. The 6-month and 1-year primary patency, primary assisted patency, secondary patency, and freedom from clinically-driven target lesion revascularization (CD-TLR) were evaluated. Univariate and multivariate analyses were performed to identify risk factors of primary patency loss or CD-TLR. RESULTS: Seventy-nine consecutive patients (83 lesions, mean age 70.9 years, 52 men) were included. Twenty-seven limbs had lifestyle-limiting claudication and 56 limbs had critical limb ischemia. There were 73 and 10 limbs with de novo lesion and in-stent restenosis, respectively. The mean lesion length of all the patients was 22.1 cm. The mean length of chronic total occlusions (CTOs) was 8.3 cm. Severe calcification was found in 32.5% cases. The 1-year primary patency rate was 80.8% and freedom from CD-TLR was 92.2%. The bailout stenting rate was 2.4%. Patients with CTO >10 cm had significantly lower 1-year primary patency rate and freedom from CD-TLR than did patients with CTO ≤10 cm. Total length of CTO (stratified as ≤5 cm, 5-10 cm, >10 cm) was identified as an independent risk factor of 1-year primary patency loss and CD-TLR. CONCLUSION: DA + DCB appears to be a safe and effective endovascular therapy to treat FPAD in real-world clinical practice, with a promising 1-year patency rate with a low rate of bailout stenting.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Feng Z, Yang S, Sang H, et al. One-Year Clinical Outcome and Risk Factor Analysis of Directional Atherectomy Followed With Drug-Coated Balloon for Femoropopliteal Artery Disease. J Endovasc Ther. 2021. PMID: 34251279. doi:10.1177/15266028211030527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。